Firefly Neuroscience

Company Overview

Snapshot

Founded in January 2006 by Amir Geva, Firefly Neuroscience operates with 11–50 employees. The company has raised a total of $82.59M across 11 funding rounds and went public on NASDAQ in November 2021. In May 2025, Firefly Neuroscience expanded its database, IP portfolio, and commercial footprint through the acquisition of Evoke Neuroscience, Inc.

Business overview

Firefly Neuroscience develops Brain Network Analytics (BNA™) technology, which provides an objective assessment of brain function and cognition. This technology records and compares brain activity to an FDA-cleared, age-matched normative database using AI and advanced signal processing. The company's core product, BNA™, enables clinicians and patients to make informed decisions regarding therapy and disease management, and to track changes over time, thereby reducing subjectivity in managing mental illnesses and cognitive disorders. Firefly Neuroscience operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Decision Support, serving markets globally.

Strategic signal

In September 2025, Firefly Neuroscience partnered with HealingMaps to offer its cognitive electrophysiology analytics to over 2,500 ketamine, psilocybin, and TMS clinics across North America. This strategic partnership indicates a significant expansion of Firefly Neuroscience's commercial reach and integration of its BNA™ technology into a broader network of mental health treatment providers, signaling strong market adoption and potential for increased revenue streams.

Company Intelligence Q&A

When did Firefly Neuroscience go public?

Firefly Neuroscience went public on NASDAQ in November 2021.

What was a significant recent acquisition by Firefly Neuroscience?

In May 2025, Firefly Neuroscience acquired Evoke Neuroscience, Inc., which expanded its database, IP portfolio, and commercial footprint.

What recent partnership did Firefly Neuroscience announce?

In September 2025, Firefly Neuroscience partnered with HealingMaps to provide its cognitive electrophysiology analytics to over 2,500 ketamine, psilocybin, and TMS clinics across North America.

What was the outcome of Firefly Neuroscience's research collaborations with Takeda and Novartis?

In September 2024, Firefly Neuroscience advanced its AI-driven BNA™ technology in neuroscience drug development after completing successful research collaborations with Takeda and Novartis.

What new biomarker discovery was announced by Firefly Neuroscience?

In March 2026, Firefly Neuroscience announced the discovery of new brain wave biomarkers for the differential diagnosis of ADHD.